SeekingAlpha · Nov 9, 2026
NASDAQ · DTIL
Precision BioSciences, Inc.
Healthcare · Biotechnology
$7.28
Down-$0.29 (-3.77%)
Updated Nov 17, 2026, 3:15 AM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 64.95M
- P/E ratio
- -0.69
- Dividend yield
- 0.00%
- 52-week range
- $3.53 – $11.29
- Volume
- 204.41K
- Avg. volume
- 180.03K
Price performance · DTIL
DTIL price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
DTIL closed at $7.28 after 21 trading sessions, up 17.61% for the selected period.
- Last close
- $7.28
- Period change
- +17.61%
- Period low
- $6.19
- Period high
- $10.60
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $7.52 | $7.635 | $7.25 | $7.28 | 204.41K |
| Nov 13, 2026 | $8.15 | $8.16 | $7.52 | $7.565 | 394.64K |
| Nov 12, 2026 | $8.97 | $9.00 | $7.9716 | $8.04 | 414.48K |
| Nov 11, 2026 | $9.46 | $9.585 | $8.93 | $9.15 | 251.72K |
| Nov 10, 2026 | $9.60 | $10.02 | $9.22 | $9.50 | 352.81K |
| Nov 9, 2026 | $10.715 | $10.81 | $9.615 | $9.68 | 590.23K |
| Nov 6, 2026 | $9.80 | $10.78 | $9.07 | $10.60 | 1.23M |
| Nov 5, 2026 | $8.49 | $11.29 | $8.40 | $9.87 | 2.91M |
| Nov 4, 2026 | $7.205 | $8.13 | $7.14 | $8.12 | 402.07K |
| Nov 3, 2026 | $6.95 | $7.20 | $6.64 | $6.97 | 144.84K |
| Nov 2, 2026 | $7.06 | $7.42 | $6.82 | $6.95 | 167.79K |
| Oct 30, 2026 | $7.31 | $7.42 | $6.97 | $7.06 | 108.93K |
| Oct 29, 2026 | $7.50 | $7.82 | $7.37 | $7.44 | 165.74K |
| Oct 28, 2026 | $6.76 | $7.50 | $6.66 | $7.47 | 189.67K |
| Oct 27, 2026 | $6.39 | $6.81 | $6.29 | $6.79 | 164.25K |
| Oct 26, 2026 | $6.68 | $6.8763 | $6.37 | $6.41 | 266.68K |
| Oct 23, 2026 | $6.73 | $6.73 | $6.29 | $6.64 | 275.53K |
| Oct 22, 2026 | $6.70 | $6.925 | $6.58 | $6.78 | 132.43K |
| Oct 21, 2026 | $6.62 | $6.86 | $6.545 | $6.71 | 231.04K |
| Oct 20, 2026 | $6.09 | $6.67 | $6.09 | $6.56 | 213.66K |
| Oct 19, 2026 | $5.80 | $6.21 | $5.77 | $6.19 | 176.47K |
Latest DTIL news
The latest Smart Investors Daily articles mentioning DTIL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DTIL research
Overview
Company profile and research snapshot.
Company profile
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $15.50
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 9, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 9, 2026 | Oppenheimer | Outperform | — |
| May 27, 2026 | HC Wainwright & Co. | Buy | — |
| May 21, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 5, 2026
Precision BioSciences prices 10.24M shares at $7.75 in underwritten offering
Precision BioSciences (DTIL) announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Prec
Yahoo · Nov 5, 2026
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
DURHAM, N.C., November 05, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stoc
Yahoo · Nov 5, 2026
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C., November 05, 2026--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the first patient treated with PBGENE-DMD in the Phase 1/2 FUNCTION-DMD clinical trial for Duchenne muscular dystrophy (DMD). No serious adverse ev
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.

